5 Key Takeaways

• 1

  The TETON-1 trial evaluated inhaled treprostinil in 598 patients with idiopathic pulmonary fibrosis over 52 weeks.

• 2

  Inhaled treprostinil resulted in a smaller decline in forced vital capacity compared to placebo.

• 3

  Clinical worsening occurred in 32% of patients receiving treprostinil versus 45% receiving placebo.

• 4

  Cough was reported in 55% of patients on treprostinil, compared to 33% on placebo.

• 5

  The study noted a high rate of discontinuation of study treatment, with 41% for treprostinil and 33% for placebo.